BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20200308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20201101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20210314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20211107T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20220313T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20221106T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210119T160000
DTEND;TZID=America/New_York:20210119T180000
DTSTAMP:20210225T162543Z
CREATED:20210225T162543Z
LAST-MODIFIED:20210225T162543Z
UID:48635-1611072000-1611079200@globalbiodefense.com
SUMMARY:Immunological and Genetic Features of COVID-19 and Rapid Vaccine Development
DESCRIPTION:A virtual presentation on “Immunological and Genetic Features of COVID-19 and Rapid Vaccine Development” will be held on January 19\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speakers: \nLuigi Daniele Notarangelo\, M.D. is Senior Investigator\, Immune Deficiency Genetics Section\, NIAID/DIR. The main goal of the Immune Deficiency Genetics Section (IDGS) is to characterize the molecular and cellular mechanisms underlying primary immune deficiencies\, and combined immunodeficiencies (CID) in particular\, with the ultimate objective of improving diagnosis and treatment of these conditions. Luigi D. Notarangelo received his M.D. from the University of Pavia\, Italy. After completing training in pediatrics\, subspecialty training in allergy/immunology\, and human genetics at the University of Pavia and a postdoctoral internship with David Nelson\, M.D.\, at the Metabolism Branch\, National Cancer Institute\, he was appointed associate professor and subsequently full professor of pediatrics at the University of Brescia\, Italy\, where he chaired the department of pediatrics between 2000 and 2006. In November 2006\, he joined the division of immunology at Boston Children’s Hospital\, Harvard Medical School\, as professor of pediatrics. In October 2016\, he joined the Laboratory of Host Defenses. Dr. Notarangelo is a leader in the study of the molecular and cellular mechanisms of human primary immune deficiencies and in the treatment of these disorders. He has served as president of the European Society for Immune Deficiencies and of the Clinical Immunology Society. He has received numerous national and international awards. \nBarney S. Graham\, M.D.\, Ph.D. is Senior Investigator\, Viral Pathogenesis Laboratory and Translational Science Core\, NIAID Vaccine Research Center (VRC). Dr. Graham serves as Deputy Director of the NIAID Vaccine Research Center and assists the Director in establishing and focusing the scientific direction for the VRC as a premier intramural research organization. As Chief of the Viral Pathogenesis Laboratory\, Dr. Graham also leads the development efforts for COVID-19 vaccines and universal influenza vaccines. In addition\, he supports VRC product development through strategic advice on vaccine design as well as pre-clinical and clinical evaluation. Dr. Graham is an immunologist\, virologist\, and clinical trials physician whose primary interests are viral pathogenesis\, immunity\, and vaccine development. His laboratory is focused on respiratory viral pathogens\, pandemic preparedness\, and emerging viral diseases. He applies structural biology\, protein engineering\, and other new technologies to create vaccines for unmet needs and emerging threats advancing the principles of precision vaccinology. He has been involved in the clinical evaluation of candidate vaccines for more than 30 years and has an ongoing interest in science education and expanding research opportunities for underrepresented minorities. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/immunological-and-genetic-features-of-covid-19-and-rapid-vaccine-development/
LOCATION:https://videocast.nih.gov/watch=41282
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210203T140000
DTEND;TZID=America/New_York:20210203T150000
DTSTAMP:20210130T234651Z
CREATED:20210130T234547Z
LAST-MODIFIED:20210130T234651Z
UID:48420-1612360800-1612364400@globalbiodefense.com
SUMMARY:ZOHU Call - Zoonoses & One Health Updates
DESCRIPTION:Zoonoses & One Health Updates (ZOHU) Calls are one-hour monthly webinars that provide timely education on zoonotic and infectious diseases\, One Health\, antimicrobial resistance\, food safety\, vector-borne diseases\, recent outbreaks\, and related health threats at the animal-human-environment interface.\n\nThe following is the agenda for the February 3\, 2021 ZOHU Call:\n\nOne Health News from CDC\nCasey Barton Behravesh\, MS\, DVM\, DrPH\, DACVPM\nCaptain\, U.S. Public Health Service\nDirector\, One Health Office\nCenters for Disease Control and Prevention\ndlx9@cdc.gov \nNASA and NOAA Earth Observations for Health and Air Quality Application\nJohn Haynes\, MS\nProgram Manager\, Health and Air Quality Applications\nNational Aeronautics and Space Administration Earth Science Division\njhaynes@nasa.gov\nAND\nJuli M. Trtanj\, MES\nNOAA One Health and Integrated Climate Research Lead\nNational Oceanic and Atmospheric Administration Climate Program Office\njuli.trtanj@noaa.gov \nSurveillance for Harmful Algal Bloom Events and Associated Human and Animal Illnesses — One Health Harmful Algal Bloom System\, United States\, 2016–2018\nVirginia A. Roberts\, MSPH\nEpidemiologist\nWaterborne Disease Prevention Branch\nNational Center for Emerging and Zoonotic Infectious Diseases\nCenters for Disease Control and Prevention\nevl1@cdc.gov \nExploration of Decontamination Strategies for Odor Detection Canines\nJulia Patrone\, PhD\nSenior Scientist\nJohns Hopkins Applied Physics Laboratory\njulia.patrone@jhuapl.edu\nAND\nKaren Meidenbauer DVM\, MPH\nSenior Scientist/Veterinarian\nJohns Hopkins Applied Physics Laboratory\nkaren.meidenbauer@jhuapl.edu \nThe target audience for ZOHU Calls include: \n\nAcademics\nAdministrators\nAgriculture\nAnimal health officials\nAnimal industry\nEnvironmental health professionals\nEpidemiologists\nHealth educators and communicators\nHuman health professionals\nLaboratorians\nNon-governmental organizations\nProgram managers\nPublic health professionals\nStudents\nVeterinarians/vet technicians\nWildlife officials\n\n\nA captioned recording will be posted within 30 days after the call.
URL:https://globalbiodefense.com/event/zohu-call-zoonoses-one-health-updates/
LOCATION:https://cdc.zoomgov.com/j/1611576470?pwd=bUxSZGk3TCt5dGhCSkg5cko1dGk5Zz09
CATEGORIES:Conference,Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210206
DTEND;VALUE=DATE:20210207
DTSTAMP:20200212T000700Z
CREATED:20200212T000357Z
LAST-MODIFIED:20200212T000700Z
UID:39317-1612569600-1612655999@globalbiodefense.com
SUMMARY:Application Deadline: Expanding Existing Research Grants\, CRADAs for Novel Coronavirus Response
DESCRIPTION:A Notice of Special Interest (NOSI) was issued on Feb. 6\, 2020 to highlight the urgent need for research on the 2019 novel Coronavirus (2019-nCoV) jointly by National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of General Medical Sciences (NIGMS). \nApplications will be accepted on a rolling basis from February 6\, 2020 through February 6\, 2021 by 5:00 PM local time of the applicant organization. This NOSI expires on February 6\, 2021. An application submitted in response to this NOSI that is received on February 6\, 2021 or later\, will be withdrawn. \nRead more about this opportunity in Funding News \n  \n## \nGlobal Biodefense provides this information as a courtesy. Information is subject to change. Please check the funding opportunity sponsor website to verify the most current status.
URL:https://globalbiodefense.com/event/application-deadline-expanding-existing-research-grants-cradas-for-novel-coronavirus-response/
LOCATION:Global Biodefense Calendar
CATEGORIES:Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210209T110000
DTEND;TZID=America/New_York:20210209T150000
DTSTAMP:20201127T192957Z
CREATED:20201127T192831Z
LAST-MODIFIED:20201127T192957Z
UID:48059-1612868400-1612882800@globalbiodefense.com
SUMMARY:Envisioning a Transformed Clinical Trials Enterprise for 2030 - Session 2
DESCRIPTION:The National Academies’ Forum on Drug Discovery\, Development\, and Translation will host a virtual public workshop on Feb 9\, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. \nThis virtual public workshop will provide a venue for stakeholders to consider a transformed clinical trial enterprise for 2030. Workshop participants will consider lessons learned from progress and setbacks over the past 10 years\, since the previous workshop\, Envisioning a Transformed Clinical Trials Enterprise in the United States\, and\, looking forward\, discuss goals and key priorities for advancing a clinical trials enterprise that is more efficient\, effective\, person-centered\, inclusive\, and integrated into the health delivery system of 2030. \nThe event will consider achievable goals to enhance person-centeredness and inclusivity in the clinical trials enterprise; and discuss ways to improve public engagement and partnership. \nBackground\nClinical trials research has changed dramatically over the last decade. The biological\, physical\, and digital spheres are merging; clinical research and health care are at a critical juncture; new approaches enable the collection of data in real-world settings; and new modalities\, such as digital health technologies and artificial intelligence applications\, are changing possibilities for the conduct of clinical research. \nA planning committee of the National Academies of Sciences\, Engineering\, and Medicine will plan and conduct a virtual public workshop designed to consider a transformed clinical trial enterprise for 2030\, featuring invited presentations and discussions on: \n\nLessons learned from progress and setbacks over the past 10 years.\n\n\nHow an envisioned 2030 clinical trials enterprise might differ from the current system.\n\n\nKey priority challenges and opportunities when it comes to the 2030 clinical trials enterprise.\n\n\nThe following core themes in framing a 2030 agenda:\n\n\nDiversity and inclusion of clinical trial participants\nConvergence of clinical research and clinical practice\nClinical trial data sharing\nIncorporation of new technologies into drug research and development\nWorkforce and career development\nPublic engagement and partnership\nRegulatory Environment\nCultural and Financial Incentives\n\n\nPractical short- and long-term goals for improving the efficiency\, effectiveness\, person-centeredness\, inclusivity\, and integration with healthcare of the clinical trials enterprise.\n\nFor additional information on the workshop series\, please visit the project page.
URL:https://globalbiodefense.com/event/envisioning-a-transformed-clinical-trials-enterprise-for-2030-session-2/
LOCATION:https://www.nationalacademies.org/event/02-09-2021/envisioning-a-transformed-clinical-trials-enterprise-for-2030-a-virtual-workshop-webinar-session-2
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20201127T225153Z
CREATED:20201127T225153Z
LAST-MODIFIED:20201127T225153Z
UID:48080-1614038400-1614297599@globalbiodefense.com
SUMMARY:Systematizing the One Health Approach in Preparedness and Response Efforts for Infectious Disease Outbreaks
DESCRIPTION:A virtual meeting hosted by the National Academies on February 23-25\, 2021 will examine ways to systemize and integrate the One Health approach as part of outbreak prevention\, detection\, preparedness\, and response efforts. \nThe workshop will explore research opportunities\, multi-sectoral collaboration mechanisms\, community engagement strategies\, educational opportunities\, and policies that can effectively implement the core capacities and interventions of One Health principles to strengthen national health systems and enhance global health security. \nSession 1 will take place Tuesday\, 23 February 2021 from 10:00am – 1:00pm EST. The first day will focus on the past – what One Health has accomplished thusfar\, and taking a look at the current state of affairs around the world. The “response” facet of outbreak preparedness will be highlighted. \nSession 2 will take place Wednesday\, 24 February 2021 from 10:00 – 1:00pm EST. The second day will focus on the present – what critical changes need to be made right now to incorporate One Health into national and global health systems? The “surveillance and detection” facet of outbreak preparedness will be highlighted. \nSession 3 will take place Thursday\, 25 February 2021 from 10:00am – 1:00pm EST. The third and final day will focus on the future – what capacities do we need to build down the line to ensure global health security? What lessons have we learned that can help pinpoint priority actions for incorporating One Health into national healthcare systems? The “forecasting and predicting” facet of outbreak preparedness will be highlighted. The third day will also include breakout room discussions recapping topical throughlines from throughout the 3-day workshop. \nSpecifically\, the workshop will feature invited presentations and discussions on the following: \n\nStrategies to systematize One Health in national prevention\, detection\, preparedness\, and response efforts;\nA review of One Health programs integrated into national and global public health efforts to learn what programs are current in effect:\nIntegration of animal and human health surveillance systems for cross-reporting to better understand pathogens in animals before (or after) spill-over to humans;\nFeasibility of introducing and integrating One Health into existing coordination mechanisms\, and into national action plans based on the Joint External Evaluation;\nStrengthening the global health workforce with One Health capacities;\nPolicies that underscore the interconnectedness of animal\, human\, and environmental health;\nImplications of using a One Health approach to improve preparedness vs. a reactionary response that is required to create medical countermeasures after outbreak onset;\nPromising practices for engaging with communities and influencing behaviors that lower the risk of infectious disease infection through the One Health approach;\nThe tension between public health needs\, the private sector and data sharing within the One Health context in preparedness and response efforts; and\nPotential priority actions to unite organizations – public and private\, domestic and international – in efforts to overcome newly discovered hurdles based on lessons learned from the COVID-19 pandemic.\n\nLearn more: https://bit.ly/nasem-one-health
URL:https://globalbiodefense.com/event/systematizing-the-one-health-approach-in-preparedness-and-response-efforts-for-infectious-disease-outbreaks/
LOCATION:
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210224T130000
DTEND;TZID=America/New_York:20210224T140000
DTSTAMP:20210217T195453Z
CREATED:20210217T195453Z
LAST-MODIFIED:20210217T195453Z
UID:48474-1614171600-1614175200@globalbiodefense.com
SUMMARY:COVID-19 Response Updates and Resources from CDC and the Ad Council
DESCRIPTION:This webinar will give participants the opportunity to hear from the nation’s premier public health organization\, the CDC and a second leadership organization in the public service advertising and social marketing sector\, The Ad Council. Both will share information and resources to help inform your local COVID-19 response messaging. The webinar will include time for Q&A from the audience. \nJohn Auerbach\, President and CEO\, Trust for America’s Health (Moderator) \nAnne Schuchat\, Principal Deputy Director\, Office of the Director\, CDC \nCharysse Nunez\, Insights Lead\, COVID Campaign\, The Ad Council \nJudy Monroe\, President and CEO\, CDC Foundation (Q&A facilitator)
URL:https://globalbiodefense.com/event/covid-19-response-updates-and-resources-from-cdc-and-the-ad-council/
LOCATION:https://trustforamericashealth.webex.com/mw3300/mywebex/default.do?nomenu=true&siteurl=trustforamericashealth&service=6&rnd=0.019950858468937516&main_url=https://trustforamericashealth.webex.com/ec3300/eventcenter/event/eventAction.do%3FtheAction%3Ddetail%26%26%26EMK%3D4832534b00000004fd235543fe6bef08a6aecb3a4969a43ac215f8ae05a81cb8f3d6c7b8a899c6c6%26siteurl%3Dtrustforamericashealth%26confViewID%3D184599983942570680%26encryptTicket%3DSDJTSwAAAAR8fYe4Pp0F9RzMNsCO_2IqHfONrIMV-htYi1Vc2K5nTw2%26
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210225T143000
DTEND;TZID=America/New_York:20210225T160000
DTSTAMP:20210224T192420Z
CREATED:20210124T192057Z
LAST-MODIFIED:20210224T192420Z
UID:48614-1614263400-1614268800@globalbiodefense.com
SUMMARY:Defend The Flock: How Avian Influenza Affects Us All
DESCRIPTION:The United States Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) invites you to join poultry health experts for a webinar on Thursday\, February 25. As part of Bird Health Awareness Week\, several poultry experts from across the country will host a discussion about what avian influenza is\, how it impacts different segments of the poultry industry and the surrounding communities\, and how to prevent the disease from affecting our Nation’s flocks. \nFrom December 2014 through June 2015\, the U.S endured its largest animal health emergency to date\, with more than 200 commercial and backyard premises affected with highly pathogenic avian influenza (HPAI) across the country\, and leading to the death of over 50 million birds. Recently\, cases of HPAI were confirmed in Europe\, Asia and Africa\, and many poultry owners and producers are concerned and want to take steps to protect their flocks. \nThe “Defend The Flock: How Avian Influenza Affects Us All” webinar will take place on Thursday\, February 25 from 2:30-3:30 PM EST. Register for this FREE webinar today at http://bit.ly/BirdHealthWebinar.
URL:https://globalbiodefense.com/event/defend-the-flock-how-avian-influenza-affects-us-all/
LOCATION:https://us02web.zoom.us/webinar/register/WN_4L-8gBAzRMiJ41EnnPJrhA
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210301
DTEND;VALUE=DATE:20210302
DTSTAMP:20210225T153427Z
CREATED:20210125T152534Z
LAST-MODIFIED:20210225T153427Z
UID:48617-1614556800-1614643199@globalbiodefense.com
SUMMARY:Rare Disease Day at NIH 2021 - Virtual Conference
DESCRIPTION:Rare Disease Day at NIH will be held virtually on Monday\, March 1\, 2021\, from 10:30 a.m. to 5:30 p.m. EST. This year’s event will feature interactive panel discussions\, rare stories through TED-style talks and more. \nThe event is free and open to the public\, including patients\, patient advocates\, health care providers\, researchers\, trainees\, students\, industry representatives and government employees. \nEach year\, the slogan for NIH’s event has been “Patients & Researchers — Partners for Life.” This slogan aligns with NCATS’ philosophy that researchers must work closely with patients\, families\, caregivers and advocacy groups to maximize the chances for success in advancing rare diseases research. This philosophy has been put into practice in NCATS’ Toolkit for Patient-Focused Therapy Development\, Rare Diseases Clinical Research Network(link is external)\, Therapeutics for Rare and Neglected Diseases program\, Rare Diseases Registry Program (RaDaR) and Genetic and Rare Diseases Information Center\, among other efforts. \nAbout 7\,000 rare diseases affect humans\, of which only a few hundred have any treatment. Although each rare disease affects fewer than 200\,000 Americans\, in total\, these illnesses affect an estimated 30 million people in the United States. \nCredit: CDC\nSince rare diseases often are difficult to diagnose\, it can take years to obtain an accurate diagnosis. Even after a proper diagnosis\, treatment often is unavailable\, because only about 5 percent of rare diseases have a treatment approved by the FDA. \nAs a result\, rare diseases are devastating and costly for patients\, their families and the nation as a whole. Most rare diseases are serious or life-threatening\, chronic and progressive disorders that place substantial medical and financial burdens on patients and their families. \nThrough its work to improve the science of collaboration\, NCATS supports collaborative and innovative approaches to research on rare diseases. NCATS’ Office of Rare Diseases Research (ORDR) facilitates and coordinates NIH-wide activities involving research for a broad array of rare diseases. These efforts have the potential to speed development of treatments for multiple rare diseases and ultimately help more patients more quickly. Learn more about ORDR and NCATS’ rare disease research programs and access shareable resources to help raise awareness about rare diseases.
URL:https://globalbiodefense.com/event/rare-disease-day-at-nih-2021-virtual-conference/
LOCATION:
CATEGORIES:Awareness Event,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/02/rare-disease-day-nih-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210302
DTEND;VALUE=DATE:20210306
DTSTAMP:20210225T232420Z
CREATED:20210225T232420Z
LAST-MODIFIED:20210225T232420Z
UID:48654-1614643200-1614988799@globalbiodefense.com
SUMMARY:Effectiveness of Non-Vaccine Influenza Control Measures
DESCRIPTION:The National Academies will host a first committee meeting on Effectiveness of Non-Vaccine Influenza Control Measures on March 2-5\, 2021 in virtual format. \nThe event supports the Health and Medicine Division’s Public Health Interventions and Countermeasures for Advancing Pandemic and Seasonal Influenza Preparedness and Response project. \nThe global response to COVID-19 has pushed the boundaries of preparedness for a respiratory virus. At the request of the Office of Global Affairs within the U.S. Department of Health and Human Services\, the National Academies has convened a committee to analyze how the response to COVID-19 and related events could inform efforts to strengthen future preparedness for and response to seasonal and pandemic influenza. This committee will review non-vaccine public health interventions and countermeasures that can be vital to mitigating the spread and impact of a respiratory virus both before and after vaccines are available. \n\n\nThese virtual events (March 2\, 4\, and 5) will feature speakers with expertise on therapeutics\, non-vaccine public health interventions\, as well as surveillance for influenza and COVID-19. \nPlease visit the Effectiveness of Non-Vaccine Influenza Control Measures webpage for more information. \n 
URL:https://globalbiodefense.com/event/effectiveness-of-non-vaccine-influenza-control-measures/
LOCATION:
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210302T160000
DTEND;TZID=America/New_York:20210302T180000
DTSTAMP:20210225T162756Z
CREATED:20210225T154652Z
LAST-MODIFIED:20210225T162756Z
UID:48622-1614700800-1614708000@globalbiodefense.com
SUMMARY:RNA Viruses: How They Do What They Do
DESCRIPTION:A virtual presentation on “RNA Viruses: How They Do What They Do” will be held on March 2\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speakers \nDr. Nihal Altan-Bonnet received her B.A. in biology and chemistry from Hunter College\, New York in 1992 and her Ph.D. in cell biology from The Rockefeller University in 1998. She then conducted postdoctoral research with Dr. Jennifer Lippincott-Schwartz at the National Institute of Child Health and Development at the NIH from 1999 to 2005 before receiving a faculty position in the department of biological sciences at Rutgers University. In 2013\, Dr. Altan-Bonnet returned to the NIH as an Earl Stadtman Investigator\, becoming head of the Laboratory of Host-Pathogen Dynamics at the NHLBI and was promoted to tenured Senior investigator in 2017. Dr. Altan-Bonnet has been recognized several times for her outstanding research\, receiving the Presidential Early Career Award in Science and Engineering (PECASE) in 2012\, being named the John J. Holland lecturer at the American Society of Virology in 2017\, and receiving the Norman Salzman Mentor Award in Virology in 2018. Dr. Altan-Bonnet was also named a Kavli Fellow and Scialog Fellow from 2013-2016. She is an Associate editor at the Molecular Biology of the Cell and is a member of the American Societies for Virology\, Microbiology\, and Cell Biology. \nKarla Kirkegaard\, Ph.D.\, is the Violetta L. Horton Research Professor of Genetics and former Chair of the Department of Microbiology and Immunology in the Stanford University School of Medicine. She received her Ph.D. in Biochemistry and Molecular Biology with James C. Wang at Harvard University\, and performed her postdoctoral work in the laboratory of David Baltimore at the Whitehead Institute. As an Assistant and Associate Professor at the University of Colorado in Boulder\, she received numerous awards\, including a fellowship from the David and Lucile Packard Foundation\, an American Cancer Society Young Investigator Award\, a Searle Scholar Award\, and sponsorship by the Howard Hughes Medical Institute. Dr. Kirkegaard combined her interests in biochemistry\, cell biology\, and genetics in the study of RNA virology\, using poliovirus and other positive-strand RNA viruses to understand the cell biology of viral infections and the genetics of viral variability. Since her move to Stanford University School of Medicine in 1996\, her interests have focused increasingly on the impact of basic science discoveries on the transmission of viruses in infected hosts. Kirkegaard’s honors include an Ellison Foundation Senior Scholar Award in Global Infectious Disease and\, in 2006\, the NIH Director’s Pioneer Award\, for her approach to guide the selection of antiviral targets with the goal of suppressing the drug-resistant RNA genomes that will inevitably be formed due to the high error rates of RNA replication. She has been recently elected as a Member of the National Academies of Arts and Sciences and a Fellow of the American Association for the Advancement of Science. Her work continues to focus on the mechanisms of diversity and propagation of viruses and suppression of this diversity and spread. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/rna-viruses-how-they-do-what-they-do/
LOCATION:https://videocast.nih.gov/watch=41288
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210302T170000
DTEND;TZID=America/Los_Angeles:20210302T190000
DTSTAMP:20210223T213836Z
CREATED:20210223T211535Z
LAST-MODIFIED:20210223T213836Z
UID:48583-1614704400-1614711600@globalbiodefense.com
SUMMARY:COVID Seminar Series - Hindsight is 2020
DESCRIPTION:The Pacific Northwest National Laboratory will host a COVID Seminar Series event on March 2: “Hindsight is 2020”. The Community Science and Technology Seminar Series was launched to help the general public better understand and explore how science transforms our world. \nDuring this inaugural COVID-19 seminar series talk\, Dr. Steven Wiley will discuss the differences in symptoms between a cold\, the flu\, and COVID-19\, in addition to the larger scientific story of COVID-19. What are the dangers\, really? What lessons have we learned over the last few months and how does COVID compare to past viral pandemics? What’s left for us to uncover? \nABOUT THE SPEAKER \nDr. Wiley is a systems biologist in the Functional and Systems Biology group in the Environmental Molecular Sciences Division and the Environmental Molecular Sciences Laboratory (EMSL) user program. He combines molecular and cellular biology with both biochemical and optical assays to generate quantitative data to build computational models of cellular processes. Wiley is the author or co-author of more than 200 scientific publications\, including more than 130 articles in peer-reviewed scientific journals\, and 30 review articles and book chapters. He also has written several commercial graphics and data analysis software packages. Dr. Wiley has served as a reviewer for more than 30 scientific journals\, is an associate editor of Frontiers in Genetics and is on the editorial board of The Scientist and BMC Biology. \nPlease visit the PNNL website for more information.
URL:https://globalbiodefense.com/event/demystifying-covid-seminar-series-hindsight-is-2020/
LOCATION:https://pnnl.zoomgov.com/webinar/register/WN_t1dKS6PtSz21y58_5qngrg
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210304T100000
DTEND;TZID=America/New_York:20210304T133000
DTSTAMP:20210225T172409Z
CREATED:20210225T172409Z
LAST-MODIFIED:20210225T172409Z
UID:48646-1614852000-1614864600@globalbiodefense.com
SUMMARY:Vulnerabilities in U.S. Chemical Weapons Detection\, Identification\, and Tracing
DESCRIPTION:The National Academies will host an expert discussion on Identifying and Accounting for Vulnerabilities in U.S. Chemical Weapons Detection\, Identification\, and Tracing Capabilities on March 4\, 2021. \nThe meeting is open to the public in virtual format and is part of a larger 2-day meeting of the Board on Chemical Sciences and Technology. \nThe Chemical Weapons session will explore the current state of the science in the field of chemical weapons detection\, identification\, and tracing\, and will highlight opportunities for additional research in this space. \nChemical weapons remain an ever-present\, high level threat to domestic and global security despite international efforts to regulate the weaponization of chemical agents. The recent use of deadly chemical agents in alleged assassination attempts of civilian targets has elevated interest in and attention to these weapons. This heightened awareness underscores critical knowledge gaps in the development of chemical weapons detection and identification technologies. The targeted deployment of chemical agents also demonstrates the advantages of employing forensic chemistry to investigate and trace chemical weapons. \nLeaders of panel discussions and Q&A sessions include: \n\nDr. Audrey M. Williams\, Director\, Forensic Science Center\, Lawrence Livermore National Laboratory (LLNL)\nDr. Carlos G. Fraga\, Senior Research Scientist\, Chemical and Biological Signatures Group\, Pacific Northwest National Laboratory (PNNL)\nDr. John Fortner\, Associate Professor of Chemical and Environmental Engineering at the Yale School of Engineering and Applied Science\nJennifer Sinclair Curtis\, University of California\, Davis\nScott Collick\, DuPont\n\nThis event will be webcast from the NASEM webpage. Registration is free and available here.
URL:https://globalbiodefense.com/event/vulnerabilities-in-u-s-chemical-weapons-detection-identification-and-tracing/
LOCATION:https://www.nationalacademies.org/event/03-03-2021/board-on-chemical-sciences-and-technology-march-2021-meeting
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210304T120000
DTEND;TZID=America/New_York:20210304T130000
DTSTAMP:20210226T161901Z
CREATED:20210126T161411Z
LAST-MODIFIED:20210226T161901Z
UID:48672-1614859200-1614862800@globalbiodefense.com
SUMMARY:Integrating Inflammation and Coagulation in COVID-19
DESCRIPTION:The National Institutes of Health COVID-19 Scientific Interest Group will host a webcast on Integrating Inflammation and Coagulation in COVID-19 on March 4\, 2021. \nAbout the Speaker \nYogen Kanthi\, M.D.\, NHLBI Lasker Scholar\, NIH \nSpeaker Yogen Kanthi is a cardiologist and clinical vascular medicine specialist. His laboratory aims to understand how inflammation and coagulation contribute to vascular disease. He is interested in developing a deeper understanding of how innate immune circuits and communicate with coagulation and the vessel wall to license or restrict thrombosis. \nPlease visit the NIH VideoCast website for more information.
URL:https://globalbiodefense.com/event/integrating-inflammation-and-coagulation-in-covid-19/
LOCATION:https://videocast.nih.gov/watch=41450
CATEGORIES:Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210306
DTEND;VALUE=DATE:20210311
DTSTAMP:20210226T172535Z
CREATED:20201126T162842Z
LAST-MODIFIED:20210226T172535Z
UID:48678-1614988800-1615420799@globalbiodefense.com
SUMMARY:CROI 2021 - Conference on Retroviruses and Opportunistic Infections
DESCRIPTION:The 2021 Conference on Retroviruses and Opportunistic Infections (CROI) will be held March 6-10\, 2021 in a virtual format. \nThe synergy of basic science and clinical investigation has been a major contributor to the success of the meeting. CROI has facilitated the presentation of important discoveries in the field\, thereby accelerating progress in HIV and AIDS research. As always\, the best and most consequential original research will define the science at virtual CROI 2021 (vCROI 2021)\, which will include research in HIV\, hepatitis viruses\, SARS-CoV-2\, and other viral infections and their related conditions. \nHighlighted sessions include: \n\nAdvances in Molecular Virology of HIV and SARS-CoV-2 – Frank Kirchhoff\, Ulm University Medical Center\nAdvances in COVID-19 Treatments and Controlling the Epidemic – Jürgen Rockstroh\, Medizinische Universitatsklini\nVaccine Nationalism is Killing Us: How Inequities in Research and Access to SARS-CoV-2 Vaccines Will Perpetuate the Pandemic – Gregg Gonsalves\, Yale University\, Fatima Hassan\, Health Justice Initiative\nLessons from the Concurrent HIV/AIDS and COVID-19 Pandemics: A Two-Way Street\nAnthony S. Fauci\, National Institutes of Health\nSARS-CoV-2–Specific and Cross-Reactive T-Cell Responses – Daniela Weiskopf\, La Jolla Institute for Immunology\nMaking Sense of Study Design Differences Between COVID-19 Platform Trials – Lori Dodd\, National Institutes of Health\nDesign of Current and Future COVID-19 Vaccine Efficacy Trials – Holly Janes\, Fred Hutchinson Cancer Research Center\nRapid Genomic Sequencing for Management of COVID-19 – Kwok-Yung Yuen\, The University of Hong Kong\nImaging Viral Life Cycles – Hans-Georg Kräusslich\, Heidelberg University\nSARS-CoV-2 Evolution in Populations and Individuals – moderated by Katharine J. Bar\, University of Pennsylvania and John Coffin\, Tufts University\nContact Tracing in Controlling Epidemics: Is the Juice Worth the Squeeze? – Moderator: Wafaa El-Sadr\, Columbia University\nOrigin\, Pathogenicity\, and Immune Evasion Strategies of Human Coronaviruses – Volker Thiel\, University of Bern\nImmune Responses to SARS-CoV-2 – Akiko Iwasaki\, Yale University\nThe Potential of Long-Acting Injectable Drugs for Prevention and Treatment of Tuberculous – Eric Nuermberger\, Johns Hopkins University\nAdvances in Pediatric TB Prevention and Treatment – Nicole Salazar-Austin\, Johns Hopkins University\nHumoral Responses Against the SARS-CoV-2 Spike – Andrés Finzi\, University of Montreal\nT-Cell Immunity in SARS-CoV-2 Natural Infection and Following Vaccination – Julie McElrath\nLongitudinal Antibody Responses to SARS-CoV-2 and Emerging Variants – Katie Doores\, King’s College London\nProgramming Durable Immunity – Robert Seder\, Vaccine Research Center\nPathological B-Cell activation During SARS-CoV-2 Infection – Ignacio Sanz\, Emory University\nBreaking the B-Cell Barrier to Eliminate Viral Reservoirs – Afam Okoye\, Oregon Health Sciences University\nModels of Delivering PrEP in East Africa: Innovations and Lessons Learned – Moses Kamya\, Makerere University College of Health Sciences\nGot Anything for This Cough? New Antivirals for Treatment of SARS-CoV-2 – Davey Smith\, University of California\nBody on Fire: Multisystem Inflammatory Syndrome in Children – Elizabeth Whittaker\, Imperial College London\nThink About It: Neurologic Manifestations of COVID-19 – Benedict Michael\, University of Liverpool\n\nLive and on-demand sessions from CROI 2021 will be available to registered attendees during the conference. Thereafter\, recordings of live and on-demand sessions will be available to nonregistrants only through a paid subscription. For more information\, visit the CROI resources page.
URL:https://globalbiodefense.com/event/croi-2021-conference-on-retroviruses-and-opportunistic-infections/
LOCATION:
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210308
DTEND;VALUE=DATE:20210311
DTSTAMP:20210225T233052Z
CREATED:20210125T232650Z
LAST-MODIFIED:20210225T233052Z
UID:48656-1615161600-1615420799@globalbiodefense.com
SUMMARY:Quantum-Enabled Sensing and Imaging for Biology
DESCRIPTION:Quantum Science Concepts in Enhancing Sensing and Imaging Technologies: Applications for Biology—A Workshop will be held March 8-10\, 2021 via virtual format. \nThe National Academies of Sciences\, Engineering\, and Medicine is organizing this workshop on the research and development needs to advance biological applications of quantum-enabled sensing and imaging technologies. \nThis event is open to the public and is meant for a broad scientific audience\, including anyone with interest in biology\, chemistry\, physics\, or engineering. The workshop is intended to bring together experts working on state-of-the-art quantum-enabled technologies with scientists who are interested in applying these technologies to biological systems. Through talks\, panels\, and discussions\, the workshop will facilitate a better understanding of the current and future biological applications of quantum-enabled technologies on fields such as microbiology\, molecular biology\, cell biology\, plant science\, mycology\, and many others. Please register below\, and we will be in touch as the agenda continues to develop. \nThe presentations and discussions may explore the following: \n\nThe history of and terminology for quantum sensing and imaging technologies\, as well as any established biological applications.\nDescriptions of current biological applications of quantum sensing and imaging as well as other potential areas of biology where these technologies might be applied.\nUnderstanding what advantages are imparted by quantum-enabled sensing and imaging technologies over their classical counterparts. For example\, will these technologies provide a better signal-to-noise ratio\, better depth of interaction (to image deep-seated signals)\, or increase the spatial and temporal resolution of imaging cellular and molecular functionalities?\nDetermining what disadvantages\, strategies\, feasibility\, and technical needs must be addressed for applying the principles of quantum sensing and imaging to advance the fields of interest in biology. How might the demonstrated uses of quantum approaches in other fields be adaptable to plant science\, microbiology\, and mycology\, especially for work in intracellular molecular phenomena and intercellular interactions? What impediments must be overcome for these applications to succeed\, and what investments could help drive the convergence of these disparate fields forward?\nExploring how the applications of these technologies could have broader impacts in areas such as the development of renewable energy sources\, understanding the effects of earth systems changes on biota\, and the advancement of biotechnology.\nIdentifying the education\, training\, and workforce needs for advancing quantum sensing and imaging technologies in biology.\n\nThis workshop is made possible through the generous support of the U.S. Department of Energy – Biological and Environmental Research Program. \nRegistration is available at: https://quantum-and-bio.heysummit.com/
URL:https://globalbiodefense.com/event/quantum-enabled-sensing-and-imaging-for-biology/
LOCATION:
CATEGORIES:Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210308T140000
DTEND;TZID=America/New_York:20210308T153000
DTSTAMP:20210225T234524Z
CREATED:20210225T234524Z
LAST-MODIFIED:20210225T234524Z
UID:48658-1615212000-1615217400@globalbiodefense.com
SUMMARY:TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective
DESCRIPTION:The Transportation Research Board will host a Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective webinar on March 8\, 2021 that will delve into the pandemic’s effect on transportation. \nPresenters will discuss visualizations of where these impacts have been especially notable\, including the drastic reduction in road and air traffic and in public transit ridership during early days of the pandemic. They will provide perspectives from the local\, state\, and international levels. \nHighlighted presentations include: \n\nVisualizing COVID-19 impacts on urban mobility: Kaan Ozbay\, New York University\nVisualizing COVID-19 impacts on state level-mobility: Michael Pack\, University of Maryland\nVisualizing COVID-19 impacts on air travel: Mark Duell\, FlightAware\nQuestion and answer session: Charles Lattimer\, University of Maryland\n\nThe first 60 minutes of the webinar will be for presentations and the final 30 minutes will be reserved for audience questions. \nProfessional Development Hour Information \nProfessional engineers (PEs) who register and attend the entire webinar as an individual will be awarded 1.5 Professional Development Hours (PDHs). TRB’s webinar program awards PDH credits only to the registered individual\, and not to other members of a group that view the webinar together. To be eligible for the credits\, individuals must remain signed in for the entire webinar\, including for any question and answer session following the presentations. \nThis webinar was organized by the TRB Standing Committee on Visualization in Transportation. \nLearn more at the National Academies’ Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective webpage. \n 
URL:https://globalbiodefense.com/event/trb-webinar-visualizing-effects-of-covid-19-on-transportation-a-one-year-retrospective/
LOCATION:
CATEGORIES:Continuing Education,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20210225T235017Z
CREATED:20210225T235017Z
LAST-MODIFIED:20210225T235017Z
UID:48660-1615248000-1615507199@globalbiodefense.com
SUMMARY:The Current Global Governance Landscape for Influenza
DESCRIPTION:The Health and Medicine Division of the National Academies will convene a virtual committee meeting on the Current Global Governance Landscape for Influenza on March 9-11\, 2021. \nThis first meeting of the committee will serve for the committee to begin to analyze the major global frameworks\, regulations\, and partnerships for influenza vaccine preparedness and response. \nOpen sessions will feature discussions with speakers\, including the sponsor and global health leaders\, about considerations that led to the launch of this consensus study and gaps in or barriers to implementation of current global mechanisms for influenza vaccine development\, manufacturing\, and access. The meeting will allow committee members to identify areas of concentration within the study’s statement of task and determine what information gathering will be required for to make recommendations for these areas. \nPlease visit NASEM’s Current Global Governance Landscape for Influenza Vaccines webpage for more information.
URL:https://globalbiodefense.com/event/the-current-global-governance-landscape-for-influenza/
LOCATION:
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210309T110000
DTEND;TZID=America/New_York:20210310T160000
DTSTAMP:20210226T160748Z
CREATED:20210126T154128Z
LAST-MODIFIED:20210226T160748Z
UID:48669-1615287600-1615392000@globalbiodefense.com
SUMMARY:Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic
DESCRIPTION:The National Academies will host a committee meeting on Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic: Lessons Learned from March 9-10\, 2021. \nRapid (and Precise) COVID-19 Vaccine Development\nBarney Graham\, M.D.\, Ph.D.\, Deputy Director\, Vaccine Research Center\, NIAID\, NIH \nThe COVID-19 Pandemic: The Triumphs and Challenges of Vaccine Development and Use of Animal Models in the Midst of a Pandemic\nIan Moore\, D.V.M.\, Ph.D.\, DACVP\, Investigative Veterinary Pathologist and Section Chief\, Infectious Disease\nPathogenesis Section\, NIAID\, NIH \nBringing Together Stakeholders: Users and Resources\nFranziska Grieder\, D.V.M.\, Ph.D.\, Director\, Office of Research Infrastructure Program\, Division of Program Coordination\, Planning\, and Strategic Initiatives\, NIH \nLessons Learned: NHP Supply\nKurt Derfler\, M.B.A.\, Executive Director of Operations\, Charles River Laboratories \nNonhuman Primate Importation During the SARS-CoV-2 Pandemic\nGale Galland\, D.V.M.\, M.S.\, DACVPM\, Veterinary Medical Officer\, Zoonoses Team\, Quarantine Border Health Services Branch\, Division of Global Migration and Quarantine\, CDC \nOccupational Health in a Pandemic\nMaureen Thompson\, BSN\, RN\, COHN\, RBP(ABSA)\, Safety Officer\, Yerkes National Primate Research Center\nAssociate Director\, Environmental Health and Safety Office\, Emory University \nRisk Assessment and Biosafety Support for SARS-CoV-2 and COVID-19 Research: Challenges in Established ABSL-2 and ABSL-3 Research Programs\nMolly Stitt-Fisher\, PhD\, CPH\, CBSP\, SM(NRCM)\, Rebecca Lingenfelter\, MSPH\, University Biosafety\, Officer/Associate Biosafety Officer and Alternate Responsible\, Official for Select Agents\, Department of Environmental Health and Safety\, University of Pittsburgh \nPublic Messaging and Communications About Animal-Based Research During the COVID-19 Pandemic\nJames O’Reilly\, B.A.\, President\, Massachusetts Society for Medical Research \nVirus Sequence Data During an Outbreak\nEneida Hatcher\, Ph.D.\, Contractor\, National Center for Biotechnology Information\, National Library of Medicine\,\nNIH \nThe Nonhuman Primate Model of SARS-CoV-2 to Test Therapeutic Strategies: Overcoming Challenges and Obstacles Towards Proof of Concept\nKoen Van Rompay\, D.V.M.\, Ph.D.\, Full Research Virologist\, California National Primate Research Center\nUC Davis \nFast Tracking Animal Model Development\, Collaborations\, and Research to Deliver Preclinical Data for Vaccine Antigen Selection\nIsis Kanevsky\, Ph.D.\, Director\, Vaccine Research Unit\, Pfizer \nManagement of a Nonhuman Primate Colony During SARS-CoV-2\nJoyce Cohen\, V.M.D.\, DACLAM\, Associate Director\, Division of Animal Resources\, Yerkes National Primate Research Center\, Emory University \nMaintaining Animal Research Continuity in the Time of COVID-19\nMichael J. Huerkamp\, D.V.M.\, DACLAM\nExecutive Director\, Division of Animal Resources\nEmory University \nResiliency in Animal Research Operations – COVID-19 Lessons Learned: Direct Staffing Impacts\nCDR Temeri Wilder-Kofie\, D.V.M.\, MPH\, DACLAM\, Facility Veterinarian\, Comparative Medicine Branch\, NIAID\, NIH \nResiliency in Animal Research Operations: Laboratory Animal Program Operations and Management Impacts\nJill Ascher\, M.A.\, D.V.M.\, MPH\, DACLAM\, Director\, Division of Veterinary Resources\, Office of Research Services\nNIH \nImpact of the COVID-19 Pandemic on Animal Research\nLori Palley\, D.V.M.\, DACLAM\, Assistant Director of Veterinary Services\, Center for Comparative Medicine\nMassachusetts General Hospital \nFinancial Impact of the COVID-19 Pandemic on Academic Animal Care Programs\nLucy Kennedy\, D.V.M.\, DACLAM\, Assistant Director for Clinical Services and Assistant Attending Veterinarian\, Unit for Laboratory Animal Medicine\, University of Michigan \nEvolving Prioritizations of In Vivo Research in Pharma During the COVID-19 Pandemic\nSean Maguire\, V.M.D.\, M.S.\, MRCVS\, DACLAM\, Comparative & Translational Sciences Director & Associate Fellow\, GlaxoSmithKline \nIntegrating the Institution’s COVID-19 Response Plan into the Research Animal Program\nStephen Denny\, D.V.M.\, M.S.\, DACLAM\, DACVPM\, Director\, Office of Animal Care and Use Office of Intramural Research\, NIH \nPanel Discussion – Resiliency in Animal Research Operations\nOpen panel discussion with audience participation \nPanelists: \n\nAcademia: Mike Huerkamp\, Lucy Kennedy\nGovernment: Jill Ascher\, Temeri Wilder-Kofie\, Stephen Denny\nIndustry – Pharma: Sean Maguire\nPrimate Research Center: Joyce Cohen\nAnimal Research Advocate: James O’Reilly\n\n\nMeeting Materials\n\n\n\nRapid Response Workshop Agenda\nSpeaker Abstracts\nSpeaker Biographies\n\n\nPlease visit the Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic: Lessons Learned page for more information.
URL:https://globalbiodefense.com/event/rapid-response-by-laboratory-animal-research-institutions-during-the-covid-19-pandemic/
LOCATION:
CATEGORIES:Webinar-Webcast,Workshop
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/02/rapid-response-animal-research-lab-covid-countermeasures-nasem.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210309T160000
DTEND;TZID=America/New_York:20210309T180000
DTSTAMP:20210225T163128Z
CREATED:20210225T155238Z
LAST-MODIFIED:20210225T163128Z
UID:48625-1615305600-1615312800@globalbiodefense.com
SUMMARY:Ethics in Vaccine Development\, Testing and Use Making a COVID-19 Vaccine
DESCRIPTION:A virtual presentation on “Ethics in Vaccine Development\, Testing and Use Making a COVID-19 Vaccine” will be held on March 9\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speakers \nKizzmekia Corbett\, PhD is a research fellow and the scientific lead for the Coronavirus Vaccines & Immunopathogenesis Team at the National Institutes of Health (NIH)\, National Institute of Allergy and Infectious Diseases\, Vaccine Research Center (VRC). She received a B.S. in Biological Sciences\, with a secondary major in Sociology\, in 2008 from the University of Maryland – Baltimore County\, where she was a Meyerhoff Scholar and an NIH undergraduate scholar. She then enrolled at University of North Carolina at Chapel Hill\, where she obtained her Ph.D. in Microbiology and Immunology in 2014. A viral immunologist by training\, Dr. Corbett uses her expertise to propel novel vaccine development for pandemic preparedness. Appointed to the VRC in 2014\, her work focuses on developing novel coronavirus vaccines\, including mRNA-1273\, a leading candidate vaccine against the virus that causes COVID-19. In response to the ongoing global COVID-19 pandemic\, the vaccine concept incorporated in mRNA-1273 was designed by Dr. Corbett’s team from viral sequence data and rapidly deployed to industry partner\, Moderna\, Inc.\, for U.S. Food and Drug Administration (FDA)-approved Phase 1 clinical trial\, which unprecedently began only 66 days from the viral sequence release. Following promising results in animal models and humans\, mRNA-1273 is currently in Phase 3 clinical trial. Alongside mRNA-1273\, Dr. Corbett’s team boasts a portfolio that also includes universal coronavirus vaccine concepts and novel therapeutic antibodies. Additionally\, Dr. Corbett spent several years working on a universal influenza vaccine\, which is slated for Phase 1 clinical trial. In all\, she has 15 years of expertise studying dengue virus\, respiratory syncytial virus\, influenza virus and coronaviruses. Along with her research activities\, Dr. Corbett is an active member of the NIH Fellows Committee and avid advocator of STEM education and vaccine awareness in the community. Combining her research goals with her knack for mentoring\, Dr. Corbett aims to become an independent principal investigator. \nChristine Grady\, PhD is a nurse-bioethicist and a senior investigator who currently serves as the Chief of the Department of Bioethics. Dr. Grady has authored more than 175 papers in the biomedical and bioethics literature and authored or edited several books\, including The Oxford Textbook of Clinical Research Ethics. She served from 2010-2017 as a Commissioner on the President’s Commission for the Study of Bioethical Issues. Her work is known internationally\, and she has lectured widely on ethical issues in clinical research and clinical care\, HIV disease\, and nursing. She is an elected fellow of the Hastings Center and of the American Academy of Nursing\, a senior research fellow at the Kennedy Institute of Ethics and an elected member of the National Academy of Medicine. She holds a BS in nursing and biology from Georgetown University\, a MSN. in community health nursing from Boston College\, and a PhD in philosophy from Georgetown University. She has participated in numerous intergovernmental task forces and is the recipient of several awards\, including the NIH CEO Award in 2017\, and the NIH Director’s Award in 2015 and 2017. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/ethics-in-vaccine-development-testing-and-use-making-a-covid-19-vaccine/
LOCATION:https://videocast.nih.gov/watch=41289
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210309T170000
DTEND;TZID=America/Los_Angeles:20210309T180000
DTSTAMP:20210223T212955Z
CREATED:20210223T212553Z
LAST-MODIFIED:20210223T212955Z
UID:48585-1615309200-1615312800@globalbiodefense.com
SUMMARY:Demystifying COVID: What Do Bats Have to Do With It?
DESCRIPTION:The Pacific Northwest National Laboratory will host a virtual Demystifying COVID Seminar Series event entitled\, “What Do Bats Have to Do With It?” on March 9\, 2021. \nBats\, pangolins\, and humans—oh my! This talk will explore the role wild animals play in the emergence of new diseases– including how they spread\, what symptoms they produce in humans\, how their origins influence their evolution\, and more. You will leave with a better understanding of coronaviruses prior to the COVID-19 pandemic\, currently\, and what we can prepare for in the future. \nThe Pacific Northwest National Laboratory’s Community Science and Technology Seminar Series was launched to help the general public better understand and explore how science transforms our world. \nABOUT THE SPEAKER \nDr. Amy Sims is a virologist at PNNL who studies how the DNA manipulation strategies of viral attacks widens the path to future therapies. For instance\, epigenetic modifications could help govern disease outcomes and sidestep immunity responses. She earned her PhD at Vanderbilt University Medical Center and spent fifteen years at the University of North Carolina Chapel Hill before recently coming to PNNL. \nRegister for the event here. \n  \n 
URL:https://globalbiodefense.com/event/pnnl-covid-seminar-series-what-do-bats-have-to-do-with-it/
LOCATION:https://pnnl.zoomgov.com/webinar/register/WN_6Xs9wD9yTWaCWWK0kOf7jw
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210312T110000
DTEND;TZID=America/New_York:20210312T130000
DTSTAMP:20210301T213238Z
CREATED:20210201T205228Z
LAST-MODIFIED:20210301T213238Z
UID:48716-1615546800-1615554000@globalbiodefense.com
SUMMARY:BARDA Vaccines Against AMR Threats Virtual Workshop
DESCRIPTION:Join the Biomedical Advanced Research and Development Authority (BARDA) at the Vaccines against AMR Threats virtual workshop on March 12\, 2021 from 11:00am – 1:00pm Eastern. \nMulti-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis. \nJoin the workshop to learn more about BARDA and how they plan to tackle this growing threat. \nHighlights from the agenda include: \n\nBARDA Introduction: Dr. Gary Disbrow\, BARDA Director\nCBRN Overview: Dr. Christopher Houchens\, CBRN Director\nAntibacterials Branch Overview: Dr. Mark Albrecht\, Antibacterials Branch Chief\nVaccines Branch Overview: Dr. Daniel Wolfe\, Vaccines Branch Chief (Acting)\nCARB-X Overview: Dr. Cameron Bess\, CARB-X Program Manager\nAMR Threats of Interest for Funding Opps: Dr. Julie Bergmann\, Dr. Lindsay Parish\, Dr. Rushyannah Killens-Cade\, CBRN Project Officers\nBARDA Solicitation Process: Ms. Jill Johnson\, DCMA Branch Chief\nQ&A Structured Discussion: Dr. Julie Bergmann\, Dr. Lindsay Parish\, Dr. Rushyannah Killens-Cade\, CBRN Project Officers\n\nVisit MedicalCountermeasures.gov for more information on this event. \n  \n 
URL:https://globalbiodefense.com/event/barda-vaccines-against-amr-threats-virtual-workshop/
LOCATION:
CATEGORIES:Government Hosted,Industry Day,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210316
DTEND;VALUE=DATE:20210320
DTSTAMP:20210226T142745Z
CREATED:20210226T142627Z
LAST-MODIFIED:20210226T142745Z
UID:48662-1615852800-1616198399@globalbiodefense.com
SUMMARY:Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States
DESCRIPTION:The National Academies will convene a meeting Examining the Long-term Health and Economic Effects of Antimicrobial Resistance in the United States on March 16-19\, 2021 via virtual format. \nDuring these meetings\, expert speakers will discuss GARP’s work developing treatments for drug-resistant infections and CMS reimbursement for new antibiotics. Speakers will also present on the challenges of using genomic data for surveillance and the role of next-generation sequencing and predictive modeling. \nThe following portions of the meeting are open to the public: \n\nMarch 16\, 2021\, 11:00am – 12:05pm ET\nMarch 19\, 2021\, 11:00am – 11:45pm ET\n\nThe agenda for the open session include a discussion of: \n\nGARDP and Antimicrobial Development\, Jennifer Schneider\, Senior Advisor External Affairs\, Global Antibiotic R&D\, Partnership\nInpatient Reimbursement and the Antimicrobial Market\, Anand Shah\, former Deputy Commissioner for Medical and Scientific Affairs\, FDA\nDirect\, Predictive Application of Sequencing and Informatics\, Gautam Dantas\, Professor\, Washington University School of Medicine\n\nDuring the closed sessions across both days\, the committee members will discuss draft recommendations and conclusions in the following areas: \n\nPush and Pull Incentives\nInternational Action\nHealth and Economic Burden\nSurveillance
URL:https://globalbiodefense.com/event/examining-the-long-term-health-and-economic-effects-of-antimicrobial-resistance-in-the-united-states/
LOCATION:
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210316T150000
DTEND;TZID=America/New_York:20210316T170000
DTSTAMP:20210225T160929Z
CREATED:20210225T160929Z
LAST-MODIFIED:20210225T160929Z
UID:48629-1615906800-1615914000@globalbiodefense.com
SUMMARY:Consequences of Retroviral DNA Integration to AIDS and Evolution
DESCRIPTION:An NIH virtual presentation entitled “These Viruses are Forever: Consequences of Retroviral DNA Integration to AIDS and Evolution” will be held on March 16\, 2021 as part of the 2021 Demystifying Medicine Series. \nThe 2021 Demystifying Medicine Series\, which is jointly sponsored by FAES and NIH\, will begin January 12 and includes the presentation of patients\, pathology\, diagnosis and therapy in the context of major disease problems and current research. Primarily directed toward Ph.D. students\, clinicians and program managers\, the course is designed to help bridge the gap between advances in biology and their application to major human diseases. Each session includes clinical and basic science components presented by NIH staff and invitees. All students\, fellows and staff are welcome\, as well. \nAbout the Speaker \nJohn Coffin is an American Cancer Society Professor of Molecular Biology\, Tufts Graduate School of Biomedical Sciences \nEducation:\nBA\, Biology\, Wesleyan University\nPhD\, Molecular Biology\, University of Wisconsin\, Madison\nPostdoctoral Training\, Institut für Molekularbiologie\, University of Zürich \nOur research interests revolve around obtaining a better understanding of the interaction of retroviruses with their host cells and organisms. We use simple retroviruses (avian and murine viruses) as well as HIV to elucidate the nature of the retrovirus-receptor interaction; control of viral gene expression; mechanism of retroviral genetic variation; and evolution of the host-virus relationship\, as revealed by the fossil record provided by endogenous proviruses found in the normal DNA of all vertebrates and many other species. \nPlease visit the NIH Demystifying Medicine website for more information.
URL:https://globalbiodefense.com/event/consequences-of-retroviral-dna-integration-to-aids-and-evolution/
LOCATION:
CATEGORIES:Government Hosted,Webinar-Webcast,Workshop
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210316T170000
DTEND;TZID=America/Los_Angeles:20210316T180000
DTSTAMP:20210223T213652Z
CREATED:20210223T213652Z
LAST-MODIFIED:20210223T213652Z
UID:48595-1615914000-1615917600@globalbiodefense.com
SUMMARY:Behind the Mask: The Science on Stopping the Spread
DESCRIPTION:The Pacific Northwest National Laboratory will host a virtual Demystifying COVID Seminar Series event entitled\, “Behind the Mask: The Science on Stopping the Spread” on March 16\, 2021. \nThe Pacific Northwest National Laboratory’s Community Science and Technology Seminar Series was launched to help the general public better understand and explore how science transforms our world. \nABOUT THE SPEAKER \nDr. Katrina Waters is the division director for Biological Sciences at PNNL and leads the DOE project for Viral Fate and Transport of COVID-19. Her research interests focus on understanding exposure to chemicals\, the mechanisms that lead to disease\, and network modeling of infectious diseases. She received her Ph.D. in Biochemistry from the University of Wisconsin. \nRegister for the event here.
URL:https://globalbiodefense.com/event/behind-the-mask-the-science-on-stopping-the-spread/
LOCATION:https://pnnl.zoomgov.com/webinar/register/WN_W0v876qlTD6Xs8Vmu1_DDQ
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210316T180000
DTEND;TZID=America/New_York:20210316T190000
DTSTAMP:20210313T225226Z
CREATED:20210313T225226Z
LAST-MODIFIED:20210313T225226Z
UID:48926-1615917600-1615921200@globalbiodefense.com
SUMMARY:Global Health Security and Diplomacy in the Age of Coronavirus
DESCRIPTION:The Georgetown University Global Health Initiative will host a virtual discussion on “Global Health Security and Diplomacy in the Age of Coronavirus – A Conversation with Ambassador Bonnie Jenkins” on March 16\, 2021. \nAs the COVID-19 pandemic has shown\, the need to effectively and efficiently prevent\, detect\, and respond to emerging infectious diseases and other chemical and biological threats is paramount. For global health authorities around the world\, challenges lie in promoting a collaborative and coordinated approach when implementing global health security programs. With Ambassador Bonnie Jenkins\, the class will discuss a range of topics including her experience as a leader and a woman of color in the field of global health security\, the U.S. State Department’s role in global health\, the implementation of the Global Health Security Agenda\, and the challenges of biological\, chemical\, and nuclear threats the international community faces in the future. \nFEATURED SPEAKERS \nAmbassador Bonnie Jenkins has been nominated to be undersecretary of state for arms control and international security affairs under President Joe Biden. She also is an adjunct professor at the Georgetown University School of Foreign Service and Georgetown Law; the founder and executive director of the Women of Color Advancing Peace\, Security and Conflict Transformation; and chair of the Committee on Radioactive Sources: Applications and Alternative Technologies of the National Academies of Sciences. Previously\, she served as coordinator for Threat Reduction Programs under President Barack Obama and was part of the U.S. government interagency team that launched the Global Health Security Agenda. \nJohn Monahan is the senior advisor for global health to President John J. DeGioia; senior fellow\, McCourt School of Public Policy; and senior scholar\, O’Neill Institute for National and Global Health Law. \n 
URL:https://globalbiodefense.com/event/global-health-security-and-diplomacy-in-the-age-of-coronavirus/
LOCATION:https://globalhealth.georgetown.edu/events/global-health-security-and-diplomacy-in-the-age-of-coronavirus
CATEGORIES:Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210317T110000
DTEND;TZID=America/New_York:20210317T130000
DTSTAMP:20210226T153941Z
CREATED:20210226T153751Z
LAST-MODIFIED:20210226T153941Z
UID:48665-1615978800-1615986000@globalbiodefense.com
SUMMARY:Moving Past COVID-19: Lessons Learned from Responses around the World - Syndemics Webinar
DESCRIPTION:A planning committee of the National Academies of Sciences\, Engineering\, and Medicine host a public webinar entitled ‘Moving Past COVID-19: Lessons Learned from Responses around the World’ on March 17\, 2021. \nBefore the panel discussion\, Richard Horton\, Editor-in-Chief of The Lancet\, will kick off the webinar by providing a detailed description of how public health officials and the public at large ought to understand a syndemic and its sociobiological conditions and discuss the importance of using the syndemic lens to understand disease outbreaks and responses to them. \nPanel Discussion\nLaura Helmuth\, Moderator\nEditor-in-Chief\, Scientific American \nRichard Horton\, Panelist\nEditor-in-Chief\, The Lancet \nTBD\, Panelist\nAmerican Public Health Official \nChikwe Ihekweazu\, Panelist\nDirector General\, Nigeria Centre for Disease Control \n• Outline what we might learn\, from looking at COVID-19 through the lens of a syndemic\, about the long-term consequences that are likely to surface across society and around the world – settling on specific considerations for future analysis \n• Evaluate the practical implications and applicability of using the syndemic lens\, based on lived experience of public health leadership on the ground during COVID-19 \n• Discuss key actions and topics for deeper investigation when planning for long-term\, resilient\nrecovery from COVID-19 \nPlease visit the Moving Past COVID-19: Lessons Learned from Responses around the World – Syndemics Webinar page for more information. \n 
URL:https://globalbiodefense.com/event/moving-past-covid-19-lessons-learned-from-responses-around-the-world-syndemics-webinar/
LOCATION:
CATEGORIES:Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/02/moving-past-covid-19-nasem-lessons-learned.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210323T100000
DTEND;TZID=America/New_York:20210323T153000
DTSTAMP:20210225T164735Z
CREATED:20210225T164435Z
LAST-MODIFIED:20210225T164735Z
UID:48641-1616493600-1616513400@globalbiodefense.com
SUMMARY:Holding the Line on Biodefense: Supporting First Line Response to Large-Scale Biological Events
DESCRIPTION:The Bipartisan Commission on Biodefense will host a virtual meeting on March 23\, 2021 to explore the needs of the first responder community and how the federal government can better support non-federal response to future biological incidents. \nSpeakers will include:\n▪ Philip Francisco\, Chief of Police\, Navajo Police Department\n▪ Dia Gainor\, Executive Director\, National Association of State Emergency Medical Services\n▪ Shumeane L. Benford\, Chief of Emergency Management\, City of Boston\, Massachusetts \nPlease visit the Bipartisan Commission on Biodefense website for more information.
URL:https://globalbiodefense.com/event/holding-the-line-on-biodefense-supporting-first-line-response-to-large-scale-biological-events/
LOCATION:
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210323T110000
DTEND;TZID=America/New_York:20210323T123000
DTSTAMP:20210308T083543Z
CREATED:20210308T083113Z
LAST-MODIFIED:20210308T083543Z
UID:48787-1616497200-1616502600@globalbiodefense.com
SUMMARY:Chemical Weapons Arms Control at a Crossroads: Russia\, Syria\, and the Future of the Chemical Weapons Convention
DESCRIPTION:Chemical Weapons Arms Control at a Crossroads: Russia\, Syria\, and the Future of the Chemical Weapons Convention\nMarch 23\, 2021 11:00 a.m. – 12:30 p.m. ET \nThe repeated use of chemical weapons by Syria and Russia threatens to undermine international efforts to eliminate these weapons. How will state parties to the Chemical Weapons Convention\, which bans the development and use of chemical weapons\, respond to these violations of the treaty at their annual meeting in April? \nA guest panelist will join Schar School Professor Gregory Koblentz to discuss the challenges posed by the current Russian and Syrian chemical weapons programs\, the status of international efforts to strengthen accountability for use of chemical weapons\, and the implications for global chemical weapons arms control. \nABOUT THE SPEAKERS \nDr. Hanna Notte\, Senior Non-Resident Scholar at the James Martin Center for Nonproliferation Studies (CNS)\, Berlin \nHanna Notte is a Senior Non-Resident Scholar with the James Martin Center for Nonproliferation Studies (CNS)\, currently based in Berlin\, and focusing on arms control and security issues involving Russia\, the Middle East\, their intersection\, and implications for US/European strategy and policy. Prior to that\, she was a Senior Political Officer with The Shaikh Group\, a non-profit political consultancy focused on informal diplomacy and Track II mediation in the Middle East. Dr. Notte wrote her DPhil on US-Russian cooperation in the Middle East at the University of Oxford (2017\, St. Antony’s College)\, from where she also received an MPhil in International Relations in 2014. She has held visiting research positions with the Institute of Oriental Studies in Moscow\, the Carnegie Moscow Center\, the IISS Middle East office in Manama and the Konrad-Adenauer-Foundation’s Syria/Iraq office in Beirut. She is a German national who speaks Russian\, Arabic\, and French. \nDr. John Walker\, Former Head of the Arms Control and Disarmament Research Unit (ACDRU) at the Foreign and Commonwealth Office\, United Kingdom \nDr John R Walker was Head of the Foreign and Commonwealth Office’s Arms Control and Disarmament Research Unit (ACDRU) from December 2014 to May 2020 when he retired from the FCO. He joined ACDRU in March 1985. John’s main focus was on the Biological and Toxin Weapons Convention (BTWC)\, the Chemical Weapons Convention (CWC)\, the Comprehensive Nuclear Test Ban Treaty (CTBT)\, and the UN Secretary-General’s Mechanism for investigating allegations of CBW use. In addition\, his work also included UK nuclear weapons and arms control history and nuclear disarmament verification. He is currently a Senior Associate Fellow at the European Leadership Network and a Senior Associate Fellow at the Royal United Services Institute. \nDr. Una Jacob\, Research Associate at the Peace Research Institute Frankfurt (PRIF) \nUna Jakob is a research associate at the Peace Research Institute Frankfurt (PRIF) in Germany who specialises in arms control\, disarmament\, and non-proliferation\, with a special focus on chemical and biological weapons. Her recent publications include Countering the Use of Chemical Weapons in Syria: Options for Supporting International Norms and Institutions\, written in 2019 for the EU Non-Proliferation and Disarmament Consortium\, and WMD Compliance and Enforcement in a Changing Global Context\, co-authored with Carmen Wunderlich and Harald Müller for UNIDIR (2021\, forthcoming). She holds a PhD in Political Science from Frankfurt University. \nRegister today: http://bit.ly/scharchemicalweapons
URL:https://globalbiodefense.com/event/chemical-weapons-arms-control-at-a-crossroads-russia-syria-and-the-future-of-the-chemical-weapons-convention/
LOCATION:https://gmu.zoom.us/webinar/register/WN_5HGUCsCXSSi4Pw-l1cI3WA
CATEGORIES:Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2021/03/210323-chemical-weapons-arms-control-talk.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20210323T170000
DTEND;TZID=America/Los_Angeles:20210323T180000
DTSTAMP:20210223T213409Z
CREATED:20210223T213409Z
LAST-MODIFIED:20210223T213409Z
UID:48593-1616518800-1616522400@globalbiodefense.com
SUMMARY:COVID Seminar Series: Testing\, Testing\, 1-2-3
DESCRIPTION:The Pacific Northwest National Laboratory will host a virtual Demystifying COVID Seminar Series event entitled\, “Testing\, Testing\, 1\, 2\, 3 (And What’s Up with The New Vaccine\, Anyways?)” on March 23\, 2021. \nThe Pacific Northwest National Laboratory’s Community Science and Technology Seminar Series was launched to help the general public better understand and explore how science transforms our world. \nABOUT THE SPEAKER \nDr. Kristin Omberg is the group leader of the Chemical and Biological Signatures group at PNNL. Her technical work entails developing solutions with practical utility\, in addition to policy implications. She recently worked with the Departments of Energy and Health and Human Services to evaluate methods for COVID-19 specimen analysis. She received her Ph.D. in Chemistry from the University of North Carolina at Chapel Hill. \nRegister for the event here.
URL:https://globalbiodefense.com/event/covid-seminar-series-testing-testing-1-2-3/
LOCATION:https://pnnl.zoomgov.com/webinar/register/WN_MfTKd8agQ82DiAZOkWKd9g
CATEGORIES:Conference,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210324T110000
DTEND;TZID=America/New_York:20210324T150000
DTSTAMP:20201127T193612Z
CREATED:20201127T193433Z
LAST-MODIFIED:20201127T193612Z
UID:48061-1616583600-1616598000@globalbiodefense.com
SUMMARY:Envisioning a Transformed Clinical Trials Enterprise for 2030 - Session 3
DESCRIPTION:The National Academies’ Forum on Drug Discovery\, Development\, and Translation will host a virtual public workshop on Mar 24\, 2021 as part of a web series forum of events to discuss critical policy for advancement of biopharmaceutical innovation nationally and globally. \nThis virtual public workshop will provide a venue for stakeholders to consider a transformed clinical trial enterprise for 2030. Workshop participants will consider lessons learned from progress and setbacks over the past 10 years\, since the previous workshop\, Envisioning a Transformed Clinical Trials Enterprise in the United States\, and\, looking forward\, discuss goals and key priorities for advancing a clinical trials enterprise that is more efficient\, effective\, person-centered\, inclusive\, and integrated into the health delivery system of 2030. \nThe event will consider approaches to build resilience\, sustainability\, and transparency. The discussion will include the convergence and integration of clinical research and clinical practice; data sharing and management; and efficient\, engaging scientific communication. \nBackground\nClinical trials research has changed dramatically over the last decade. The biological\, physical\, and digital spheres are merging; clinical research and health care are at a critical juncture; new approaches enable the collection of data in real-world settings; and new modalities\, such as digital health technologies and artificial intelligence applications\, are changing possibilities for the conduct of clinical research. \nA planning committee of the National Academies of Sciences\, Engineering\, and Medicine will plan and conduct a virtual public workshop designed to consider a transformed clinical trial enterprise for 2030. Key priority challenges and opportunities framing the 2030 agenda are: \n\nDiversity and inclusion of clinical trial participants\nConvergence of clinical research and clinical practice\nClinical trial data sharing\nIncorporation of new technologies into drug research and development\nWorkforce and career development\nPublic engagement and partnership\nRegulatory Environment\nCultural and Financial Incentives\nPractical short- and long-term goals for improving the efficiency\, effectiveness\, person-centeredness\, inclusivity\, and integration with healthcare of the clinical trials enterprise.\n\nFor additional information on the workshop series\, please visit the project page.
URL:https://globalbiodefense.com/event/envisioning-a-transformed-clinical-trials-enterprise-for-2030-session-3/
LOCATION:https://bit.ly/nasem-clinicaltrialenterprise
CATEGORIES:Webinar-Webcast,Workshop
END:VEVENT
END:VCALENDAR